Premium
Efficacy of reversible inhibitors of monoamine oxidase‐A in various forms of depression
Author(s) -
Lecrubier Y.,
Guelfi J. D.
Publication year - 1990
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1990.tb05319.x
Subject(s) - moclobemide , tolerability , monoamine oxidase , placebo , monoamine oxidase a , monoamine neurotransmitter , endogenous depression , depression (economics) , monoamine oxidase inhibitor , medicine , pharmacology , clinical efficacy , endogeny , psychology , psychiatry , serotonin , chemistry , antidepressant , enzyme , biochemistry , anxiety , adverse effect , receptor , alternative medicine , macroeconomics , pathology , economics
The design and the main therapeutic results of 3 controlled double‐blind studies comparing moclobemide with tricyclics and/or placebo in depressed patients are presented. Moclobemide, a reversible inhibitor of monoamine oxidase (RIMA), preferentially inhibits MAO‐A. It showed good efficacy in major depression (DSM‐III), both endogenous and non‐endogenous. The 3 studies included a total of 763 patients. The therapeutic results are similar to those observed with tricyclics (2/3 good responders). Tolerability was significantly better. The onset of action was evaluated in 2 studies and was faster in the patients treated with moclobemide. The fact that reversible inhibitors of MAO‐A demonstrate good efficacy independently of the diagnostic category of depression is an important new finding.